Anika Therapeutics (ANIK) 46.92 $ANIK SmarTrend Watching

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anika Therapeutics (ANIK) 46.92 $ANIK

SmarTrend Watching for Potential Rebound in Shares of Anika Therapeutics After 2.17% Loss
Comtex SmarTrend(R) - Fri Sep 23, 4:10PM CDT
Anika Therapeutics (NASDAQ:ANIK) traded in a range yesterday that spanned from a low of $46.62 to a high of $47.91. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $46.84 on volume of 57,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ANIK: 46.92 (-1.07)

Ligand Inks CNS License Agreement with Seelos Therapeutics
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:03AM CDT
Ligand Pharmaceuticals Incorporated (LGND) announced that it has granted licensing rights to four of its pipeline programs to Seelos Therapeutics, Inc.
CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), LGND: 115.78 (-2.38), ANIK: 46.92 (-1.07)

Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:01AM CDT
Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC.
PFE: 34.26 (+0.11), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66), NVS: 81.48 (-0.55)

Anika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society
BusinessWire - Thu Sep 22, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA" technology, today announced four data presentations on HYALOFAST, a biodegradable HA-based scaffold, at the 13th World Congress of the International Cartilage Repair Society (ICRS). The ICRS World Congress, which is being held in Sorrento, Naples, Italy during September 24-27, 2016, is the world's largest gathering of scientists, clinicians and industry participants focused on clinical cartilage repair and basic cartilage research.
ANIK: 46.92 (-1.07)

The Medicines Co. to Get BARDA Funding for Infection Drugs
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:29AM CDT
The Medicines Company (MDCO) announced a new strategic partnership with the Biomedical Advanced Research and Development Authority under which the company will receive funding for developing of new infection drug.
CBM: 46.60 (+0.30), MDCO: 40.45 (-1.05), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)

Gilead to Stop GS-5745 Development for Ulcerative Colitis
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 6:51AM CDT
Gilead Sciences (GILD) announced that it will discontinue the combined phase II/III study on GS-5745 in patients with ulcerative colitis.
GILD: 81.37 (-0.15), BMY: 56.48 (+0.06), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66)

Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 2:08PM CDT
Regeneron (REGN) and Teva have inked a deal for the development and commercialization of experimental NGF antibody, fasinumab, for chronic pain.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), ANIK: 46.92 (-1.07), REGN: 410.39 (+2.38)

Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:51AM CDT
Puma Biotechnology (PBYI) announced that its New Drug Application for neratinib has been accepted for review by the FDA.
ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07), PBYI: 68.08 (+2.10)

Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:47AM CDT
Amgen, Inc. (AMGN) announced positive top-line results from a phase III study evaluating the effect of its cholesterol-lowering medication, Repatha (evolocumab) on coronary artery disease (CAD) patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AMGN: 174.80 (-0.82), ANIK: 46.92 (-1.07)

Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 3:16PM CDT
Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.
VICL: 3.25 (+0.06), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)

BioDelivery Bunavail Gets Better Managed Care Positioning
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:42AM CDT
BioDelivery Sciences International, Inc. (BDSI) has secured improved positioning for Bunavail (buprenorphine and naloxone) under three new managed care contracts.
BDSI: 2.70 (+0.25), CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)

Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:13AM CDT
Sarepta (SRPT) announced that it gained an accelerated approval for its Duchenne muscular dystrophy (DMD) drug, Exondys 51 (eteplirsen), in the U.S.
BMRN: 97.40 (-0.05), ANIP: 66.64 (-0.17), SRPT: 57.83 (-3.14), ANIK: 46.92 (-1.07)

Bayer (BAYRY) Strives for Increased Sales & Earnings Growth
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:09AM CDT
Bayer (BAYRY) has set out encouraging growth and earnings targets across all its businesses at the "Meet Management" investor conference.
MON: 103.50 (-0.70), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)

Celgene Presents Efficacy & Safety Phase II Ozanimod Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 5:53AM CDT
Celgene (CELG) reported efficacy and safety data at 2 years from the phase II RADIANCE study on ozanimod in relapsing multiple sclerosis patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07), CELG: 109.43 (-1.14)

Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:26AM CDT
Ligand Pharmaceuticals Incorporated (LGND) announced that it has entered into a worldwide license agreement with California-based TeneoBio, Inc.
EBS: 28.36 (-0.38), ANIP: 66.64 (-0.17), LGND: 115.78 (-2.38), ANIK: 46.92 (-1.07)

Qiagen: Molecular Diagnostics & Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:14AM CDT
On Sep 13, 2016, we issued an updated research report on Qiagen NV (QGEN).
HSKA: 54.46 (-0.22), ANIP: 66.64 (-0.17), QGEN: 26.66 (-0.21), ANIK: 46.92 (-1.07)

Novavax Tanks, RSV F Vaccine Disappoints in Two Studies
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
Novavax (NVAX) announced disappointing top-line data from a couple of studies on RSV F Vaccine in older adults.
ANIP: 66.64 (-0.17), NVAX: 2.26 (+0.11), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07)

Teva/Intel Tie up for Huntington's Disease Technology Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:01AM CDT
Teva (TEVA) is collaborating with Intel (INTC) to develop a wearable device and machine learning platform that can be used for the treatment of Huntington's disease.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), INTC: 37.19 (-0.36), ANIK: 46.92 (-1.07)

Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 4:29PM CDT
Spectrum Pharmaceuticals' (SPPI) bladder cancer treatment Qapzola receives unfavorable recommendation from the FDA's advisory panel; stock down.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), SPPI: 4.72 (-0.09), ANIK: 46.92 (-1.07)

Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 9:27AM CDT
GlaxoSmithKline (GSK) reported that phase III study (ZOE-70) data on shingles vaccine candidate, Shingrix, were published in the New England Journal of Medicine.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), GSK: 43.42 (-0.16), ANIK: 46.92 (-1.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 116

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 37

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 32

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 90

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 83

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 114

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 79

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading

Top 5 Most Recently Viewed Articles

Alfa Laval Enhances Gulf Coast Support with La Porte Expansion

Updated Category News Views 183

Alfa Laval Strengthens Local Support with La Porte Service Center Alfa Laval, a world leader in heat transfer, separation, and fluid handling, is proud to announce the expansion of its Service Center in La Porte, Texas. This newly expanded facility is set to bolster the support for the Gulf Coast's industrial community, demonstrating the company’s commitment to local...

Continue Reading
AgEagle Aerial Systems Achieves Impressive Q1 Financial Gains

Updated Category News Views 209

AgEagle Aerial Systems Achieves Strong Financial Results A remarkable transformation is underway at AgEagle Aerial Systems Inc. (NYSE: UAVS), a key player in unmanned aerial systems (UAS) and sensor technology. The company has announced financial results for the first quarter of fiscal year 2025, showcasing a sharp recovery and robust performance in various financial...

Continue Reading
Empowering Future Leaders: The 6th Student Research Competition

Updated Category News Views 259

Empowering Future Leaders: The 6th Student Research Competition The Fixed Income Analysts Society (FIASI), in partnership with Fordham University's Center for Research in Contemporary Finance and the O'Shea Center for Credit Analysis and Investment, is excited to announce the launch of its highly anticipated 6th Annual FIASI – Gabelli School Student Research...

Continue Reading
LALO Tequila Unveils Unique 2025 High Proof Blanco Expression

Updated Category News Views 414

Introducing the 2025 High Proof Blanco Tequila LALO Tequila proudly presents its latest creation, the 2025 High Proof Blanco, marking a significant chapter in its celebrated line of limited-edition spirits. Scheduled just in time for Hispanic Heritage Month, this release embodies the brand’s strong cultural roots while embracing modern advancements in the tequila...

Continue Reading
TaskUs, Inc. to Reveal Q3 2024 Earnings on November 7

Updated Category News Views 95

TaskUs, Inc. to Reveal Financial Results for Q3 2024 TaskUs, Inc. (Nasdaq: TASK), a prominent leader in providing outsourced digital services and advanced customer experience, will disclose its third quarter 2024 financial results following the market's closure on November 7. Conference Call and Webcast Details Management will conduct a conference call and webcast at 5:00...

Continue Reading